Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Abulpharm | Pharmed | GlobalPharm | Berlin-Chemie / A. Mena… | CIS Pharma |
|---|---|---|---|---|---|
| Total Revenue | 341,277 | 79,521 | 74,077 | 72,981 | 65,941 |
| Total COGS | -161,618 | -36,459 | -57,229 | -65,429 | -24,855 |
| Gross Profit | 179,659 | 43,061 | 16,849 | 7,552 | 41,086 |
| Gross Margin | 52.6% | 54.2% | 22.7% | 10.3% | 62.3% |
| Other Operating Income | 7,128 | — | — | 2 | — |
| Total Operating Expenses | -6,841 | -18,312 | -4,725 | -4,935 | -7,024 |
| EBITDA | 179,946 | 24,750 | 12,124 | 2,619 | 34,062 |
| EBITDA Margin | 52.7% | 31.1% | 16.4% | 3.6% | 51.7% |
| Total D&A | 0 | -107 | -932 | -119 | -290 |
| EBIT / Operating Income | 179,946 | 24,439 | 11,192 | 2,500 | 33,772 |
| Profit Before Tax | 179,946 | 25,184 | 6,732 | 2,222 | 33,543 |
| Total Income Tax | 0 | 0 | -903 | -388 | -293 |
| Net Profit / (Loss) | 179,946 | 25,184 | 5,301 | 1,834 | 33,250 |
| Net Margin | 52.7% | 31.7% | 7.2% | 2.5% | 50.4% |
| Other Comprehensive Income | 7,858 | — | — | — | — |
| Total Comprehensive Income | 187,804 | — | — | — | — |
| Impairment (non-financial) | — | -204 | — | — | — |
| Total Other Income | — | 745 | -2,220 | — | -229 |
| Total Interest Expense | — | — | -2,239 | -278 | — |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Abulpharm | Pharma | 52.7% | 98th pct | 110 |
| CIS Pharma | Pharma | 51.7% | 97th pct | 110 |
| Pharmed | Pharma | 31.1% | 75th pct | 110 |
| GlobalPharm | Pharma | 16.4% | 52nd pct | 110 |
| Berlin-Chemie / A. Mena… | Pharma | 3.6% | 19th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.